Table 2.

Reports of CD19 CAR‐T cell therapy as second-line or first-line therapy for large B-cell lymphoma at the 2021 ASH annual meeting

Clinical trials (reference)	ZUMA-7 (axi-cel) [35]	TRANSFORM (liso-cel) [37]	BELINDA (Tisa-cel) [38]	ZUMA-12 (axi-cel) [39]
Study type	Phase 3, randomized, global CAR-T VS SOC	Phase 3, randomized, global CAR-T VS SOC	Phase 3, randomized, global CAR-T VS SOC	Phase 2, multicenter, single-arm
Indication	Second-line	Second-line	Second-line	First-line
Patients (n)	359	184	322	40
Age (median, years)	59 (21–81)	59 (20–75)	50% patients ≥ 65 years	61 (23–86)
Inclusion criteria	Aged ≥ 18 years with LBCL, ECOG PS 0–1, failure of first-line chemotherapy	Aged ≤ 75 years, eligible for ASCT, and with R/R LBCL within 12 months after first-line chemotherapy; ECOG PS ≤ 1 and adequate organ function	R/R NHL within 12 months after first-line chemotherapy	High-risk LBCL, defined by histology (double‑ or triple-hit status) or an IPI score ≥ 3, plus a positive interim PET after 2 cycles of chemotherapy
Bridging therapy permitted	No	No	Yes	NA
Response rate (ORR/CR)	ORR: 83% vs 50% CR: 65% vs 32%	ORR: 89% vs 48% CR: 66% vs 39%	ORR: 46% vs 43% CR: 28% vs 28%	ORR: 89% CR: 78%
OS	Not reached vs 35.1 months	NA	NA	12-month estimate: 91%
PFS	8.3 months vs 2 months	14.8 months vs 5.7 months	3 months vs 3 months	Not reached 12-month estimate: 73%
Grade ≥ 3 neutropenia	NA	82%	NA	68%
Grade ≥ 3 thrombocytopenia	NA	58%	NA	NA
Grade ≥ 3 CRS	6%	1.1%	5%	8%
Grade ≥ 3 ICANS	21%	0	3%	23%
Follow-up (months)	24.9	6.2	10	15.9

NA not applicable